Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Results were consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and ...
Business Insider26d
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
“C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life,” said Lydia Abad-Franch, M.D., head ...
Pharmabiz24d
Sobi & Apellis Pharma announces EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN
“C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life,” said Lydia Abad-Franch MD, head of R&D and ...
bernama1mon
Rajeswari Appointed As National Wage Negotiation Council Deputy Chairman
PUTRAJAYA, Feb 13 (Bernama) -- Former Industrial Court chairman Rajeswari Karupiah has been appointed as National Wage Negotiation Council (MPGN) deputy chairman from Feb 1, 2025 to Sept 30, 2026. The ...
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the ...
Finanznachrichten26d
Swedish Orphan Biovitrum AB: EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN
"C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life," said Lydia Abad-Franch MD, Head of R&D ...
The Star1mon
Rajeswari appointed National Wage Negotiation Council deputy chairman
PUTRAJAYA: Former Industrial Court chairman Rajeswari Karupiah has been appointed as National Wage Negotiation Council (MPGN) deputy chairman from Feb 1, 2025 to Sept 30, 2026. The Human Resources ...
Yahoo Finance26d
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has ...